NIH-funded study identifies gene variant as potential drug target
Defying the odds, an individual at high risk for early-onset Alzheimer’s disease remained dementia-free for many years beyond what was anticipated. A study funded in part by the National Institute on Aging (NIA), part of the National Institutes of Health, led researchers to suggest that a gene variant may be the key, perhaps providing a new direction toward developing a treatment.
The research focused on the case of a woman who carried a gene mutation known to cause early-onset Alzheimer’s. However, she did not develop signs of the disease until her seventies, nearly three decades after her expected age of onset. The researchers suspect that she may have been protected because in addition to the gene mutation causing early-onset Alzheimer’s in her family, she also had two copies of the APOE3 Christchurch (APOE3ch) gene variant. Findings of this case study as published in Nature Medicine suggest that two copies of the APOE3ch variant, named after Christchurch, New Zealand where it was first identified, may protect against Alzheimer’s.
“Sometimes close analysis of a single case can lead to discovery that could have broad implications for the field,” said NIA Director Richard J. Hodes, M.D. “We are encouraged that as part of our wide array of studies, this research in the unique genetic makeup of an exceptional individual can reveal helpful information.”
Early-onset Alzheimer’s disease is rare, representing less than 10% of all people who have Alzheimer’s. It typically occurs between a person’s 30s to mid-60s. Risk for both early- and late-onset Alzheimer’s disease is affected by genetic factors.
For the study, researchers led by investigators at Massachusetts General Hospital, Boston, in collaboration with the University of Antioquia, Medellin, Colombia, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, and Banner Alzheimer’s Institute, Phoenix, looked at genetic data from a Colombian family with more than 6,000 living members. Family members who carry a rare gene mutation called Presenilin 1 (PSEN1) E280A, have a 99.9% risk of developing early-onset Alzheimer’s disease.
The researchers confirmed that the woman in this case carried the PSEN1 E280A mutation, which caused early-onset Alzheimer’s in her other family members. However, she also had two copies of the APOE3ch gene variant, while no other affected family member carried two copies of this variant. Affected family members develop Alzheimer’s in their 40s, but she remained disease free until her 70s. Imaging tests showed that the woman had only minor neurodegeneration. She did have large amounts of amyloid protein deposits, a hallmark of Alzheimer’s disease, in her brain. But the amount of tau tangles, another hallmark of the disease, and the one more correlated with how thinking and memory are affected, was relatively low.
Experiments as part of the study showed that the APOE3ch variant may reduce the ability of APOE to bind to certain sugars called heparan sulphate proteoglycans (HSPG). APOE binding to HSPG has been implicated as one mechanism that may contribute to the amyloid and tau protein deposits that destroy the brain. The research suggests that a drug or gene therapy that could reduce APOE and HSPG binding has the potential to be a new way to treat or prevent Alzheimer’s disease.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- York County happenings: Alzheimer's fundraiseron February 23, 2021 at 11:58 am
Senior Commons at Powder Mill will be holding a drive-up spaghetti dinner to benefit the Alzheimer's Association, 4-6 p.m. Tuesday, March 16. Each meal will include a salad, spaghetti and meatballs, ...
- A lasting memory: Catonsville resident David McShea keeps late grandfather in mind as head of Alzheimer’s Association’s Greater Maryland Chapteron February 23, 2021 at 7:38 am
David McShea, 42, of Catonsville, serves as the executive director of the Timonium-based Alzheimer’s Association’s Greater Maryland Chapter, which provides programs and services to those in the ...
- Melanocortin receptor activation alleviates amyloid pathology and glial reactivity in an Alzheimer’s disease transgenic mouse modelon February 23, 2021 at 5:44 am
Alzheimer’s disease (AD) is among the most common neurodegenerative disorders and is characterized by the progressive deterioration of memory and cognitive functions. The major pathological hallmarks ...
- WF Nursing home helping end Alzheimer’son February 23, 2021 at 4:15 am
Alzheimer’s is a disease that some people are faced with everyday, especially in a senior care facility. “We do deal with Alzheimer’s and Dementia residents. So it is something very near and dear to ...
- Alzheimer's Association Picks Top Volunteer for Black History Monthon February 22, 2021 at 4:38 pm
The Alzheimer’s Association is commemorating Black History Month by highlighting some of their African American volunteers. This year, the Iowa chapter deemed support group facilitator, Paul Rich, as ...
- Eli Lilly CEO: We see a path to have an Alzheimer's disease-modifying drugon February 22, 2021 at 3:51 pm
Eli Lilly CEO Dave Ricks how the drugmaker has worked for decades to find a way to treat Alzheimer's disease. The company says a Phase 2 trial of donanemab reveals that the drug can slow progression ...
- Eli Lilly CEO on Alzheimer's drug candidate update, Covid antibody treatmenton February 22, 2021 at 3:15 pm
Eli Lilly CEO Dave Ricks joined Jim Cramer on "Mad Money" to discuss promising results from an Alzheimer's drug study, the company's Covid-19 antibody treatment program and migraine product.
- Immune-compromised people with HIV, APOE4 gene may have a compounded risk for Alzheimer'son February 22, 2021 at 2:24 pm
People living with the human immunodeficiency virus (HIV) who have a history of severe immunosuppression and at least one copy of the Alzheimer's disease-related gene variant APOE4, might see a ...
- Senator's bill could help Minnesotans with Alzheimer's, dementiaon February 22, 2021 at 1:00 pm
A bill sponsored by Sen. Rich Draheim, R-Madison Lake, and strongly backed by a former are police chief could help local law enforcement and first responders better assist the needs ...
- UC San Diego seeks patients to help test new treatment for Alzheimer’s diseaseon February 22, 2021 at 9:46 am
UC San Diego is seeking patients to help test a new therapy that’s meant to slow Alzheimer’s disease and possibly improve memory, a goal that has proven to be one of the toughest challenges in medical ...
via Bing News